Comparing the current results to its competitors, Mediwound Ltd reported Revenue increase in the 4 quarter 2023 by 0 % year on year. The revenue growth was below Mediwound Ltd 's competitors' average revenue growth of 415.95 %, achieved in the same quarter.
January 9, 2024
MediWound Ltd, an innovator in burn and wound care treatments, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplement to the Biologics License Application (BLA) for NexoBrid. This medical breakthrough, if approved, aims to transform the burn treatment realm by serving as an effective, non-surgical solution for pediatric patients in the U.S. suffering from severe thermal burns. This comes as great news to the medical community, especially given the potential impact on both pediatric and adult burn patients across the country. The acceptance of the supplement for review shows recognition of the potential benefits of NexoBrid, particularly in pediatric bur...
United Health Products Inc. operates using a direct-to-consumer business model, providing innovative wound care products directly to customers. The company focuses on manufacturing and distributing wound dressings for different applications, offering a comprehensive range of solutions for both medical professionals and individuals seeking reliable wound management products. Overall, United Health Products Inc. aims to deliver effective, convenient, and high-quality wound care solutions directly to their target market.
Plus Therapeutics Inc is a biotechnology company that focuses on developing precision nanoparticles for targeted therapy. They utilize their proprietary technology to create and commercialize innovative drugs for the treatment of cancer and other diseases.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
